Studies in animals have shown that it might be able to reduce symptoms of anxiety and depression
In animal studies, administration of BPC 157 following the damage caused by these drugs has shown that damage such as ventricular tachycardia, bradycardia, T wave elevation, QTc prolongation and asystole can be completely resolved in mice
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
In animal and in vitro studies, BPC-157 has been evaluated across a wide range of experimental doses, commonly reported from microgram-per-kilogram levels to higher investigational concentrations , depending on study design and experimental objectives
Centurion Peptides supplies BPC-157 at 10mg per vial, manufactured to 98% purity as verified by HPLC analysis
